News
MHRA extends Cosentyx licence for paediatric arthritis
Novartis has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Cosentyx – also known as secukinumab.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Novartis has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Cosentyx – also known as secukinumab.